BioLineRx (BLRX) Retained Earnings (2023 - 2025)
Historic Retained Earnings for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$399.6 million.
- BioLineRx's Retained Earnings fell 75.06% to -$399.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$399.6 million, marking a year-over-year decrease of 75.06%. This contributed to the annual value of -$399.8 million for FY2024, which is 236.07% down from last year.
- Per BioLineRx's latest filing, its Retained Earnings stood at -$399.6 million for Q3 2025, which was down 75.06% from -$398.6 million recorded in Q2 2025.
- BioLineRx's 5-year Retained Earnings high stood at -$342.2 million for Q1 2023, and its period low was -$399.8 million during Q4 2024.
- Over the past 3 years, BioLineRx's median Retained Earnings value was -$391.3 million (recorded in 2024), while the average stood at -$385.6 million.
- Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 1436.43% in 2024, then plummeted by 75.06% in 2025.
- BioLineRx's Retained Earnings (Quarter) stood at -$390.6 million in 2023, then fell by 2.36% to -$399.8 million in 2024, then rose by 0.05% to -$399.6 million in 2025.
- Its last three reported values are -$399.6 million in Q3 2025, -$398.6 million for Q2 2025, and -$394.7 million during Q1 2025.